Exploring Advances in Sepsis Management: Volition's Symposium
VolitionRx Limited (NYSE AMERICAN: VNRX) is at the forefront of epigenetics, continually pushing the boundaries of research and application to improve health outcomes. At this year’s ESICM Lives 2024 event, Volition will conduct a significant symposium where worldwide experts will converge to discuss innovative strategies in sepsis management using their cutting-edge Nu.Q® NETs technology.
Symposium Details and Expert Insights
The session entitled 'NETs: Casting a new light on sepsis management', scheduled for 12:30 PM CET, will feature distinguished speakers, including Professor Djillali Annane, a leading authority in the field of sepsis. Professsor Annane emphasizes the urgency of refining sepsis management protocols, stating that Nu.Q® NETs could become crucial diagnostic tools that change how clinicians approach treatment.
The Role of Nu.Q® NETs in Clinical Practice
During the symposium, research surrounding Volition's Nu.Q® NETs H3.1 assay will be highlighted. This assay is pivotal for recognizing whether patients display characteristics of treatable traits associated with sepsis. Professor Annane notes that understanding elevated levels of H3.1 in nucleosomes can provide insight into the severity of a patient’s condition, enabling early intervention.
Understanding the Impact of NETs
Neutrophil Extracellular Traps, or NETs, despite serving vital roles in neutralizing pathogens, can become harmful when they accumulate excessively. Raised NET levels contribute to tissue damage, leading to severe complications such as organ failure and sepsis which, tragically, is a leading cause of death in medical facilities globally. This underscores the importance of early detection technologies like Nu.Q® NETs, encouraging healthcare professionals to monitor patients more effectively.
Sepsis: A Global Challenge
Sepsis is responsible for over 11 million fatalities annually, necessitating immediate action in hospitals worldwide. Despite its prevalence, there remains a significant gap in awareness and implementation of effective screening and treatment protocols. Volition’s symposium aims to address this gap by sharing innovative diagnostic methodologies that can help in the detection and monitoring of sepsis.
Volition's Commitment to Health Outcomes
As a company, Volition is dedicated to using epigenetic research to enhance life quality through timely diagnostics for various health challenges. Their advancements in blood test technology aim to be both cost-effective and user-friendly, providing accessible solutions to healthcare providers globally.
The Future of Sepsis Management
Looking ahead, VolitionRx is not only focused on developing treatment innovations but also on creating a community of professionals determined to eradicate the various challenges posed by sepsis. With the insights and collaborations garnered from the symposium, there is hope for formulating improved treatment workflows that could potentially decrease sepsis-related mortality rates.
Conclusion and Call to Action
As discussions unfold at ESICM Lives 2024, Volition invites professionals from all backgrounds to engage with this vital conversation, asking the question: How can we leverage emerging technologies for better healthcare solutions? The symposium is a pivotal step toward unifying efforts in battling sepsis through innovation and collaboration.
Frequently Asked Questions
What is the focus of Volition's symposium at ESICM Lives 2024?
The symposium will explore the potential of Nu.Q® NETs technology in improving sepsis management.
Who will be presenting at the symposium?
The session will feature Professor Djillali Annane along with other esteemed experts in the field.
How does Nu.Q® NETs technology aid in diagnosing sepsis?
Nu.Q® NETs technology quantifies H3.1 nucleosomes, which can indicate the severity of sepsis in patients.
Why is sepsis a significant health concern globally?
Sepsis accounts for millions of deaths annually, highlighting the need for better diagnostics and treatment protocols.
What is Volition's mission regarding health outcomes?
Volition aims to improve diagnostics to enhance life quality and outcomes for those suffering from serious health conditions.
